• 1. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 2. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 3. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 4. An approach to the structure and vibrational analysis of cis- and trans-3-chlorostyrene through IR/Raman and INS spectroscopies and theoretical ab initio/DFT calculations?
  J. M. Granadino-Roldán,M. Fernández-Gómez,A. Navarro,T. Pe?a Ruiz,U. A. Jayasooriya Phys. Chem. Chem. Phys., 2004,6, 1133-1143
• 5. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenethylamines

Introduction to 2-(4-Chlorophenyl)Ethylamine Hydrochloride (CAS No. 2492-83-3)

2-(4-Chlorophenyl)Ethylamine Hydrochloride, identified by its Chemical Abstracts Service (CAS) number 2492-83-3, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This compound belongs to the class of amine derivatives and has garnered considerable attention due to its structural and pharmacological properties. The presence of a chloro-substituted phenyl ring and an ethylamine moiety contributes to its unique chemical behavior, making it a valuable scaffold for further derivatization and exploration in drug discovery.

The structure of 2-(4-Chlorophenyl)Ethylamine Hydrochloride features a benzene ring substituted with a chlorine atom at the para position, linked to an ethylamine group. This configuration imparts specific electronic and steric properties that influence its interactions with biological targets. The hydrochloride salt form enhances its solubility in aqueous solutions, facilitating its use in various biochemical assays and pharmaceutical formulations.

In recent years, pharmaceutical research has increasingly focused on developing novel compounds with enhanced efficacy and reduced side effects. 2-(4-Chlorophenyl)Ethylamine Hydrochloride has been investigated as a potential intermediate in the synthesis of bioactive molecules. Its amine group provides a versatile site for further functionalization, allowing chemists to explore modifications that could improve pharmacokinetic profiles or target specific biological pathways.

One of the most compelling aspects of 2-(4-Chlorophenyl)Ethylamine Hydrochloride is its role in the development of central nervous system (CNS) therapeutics. The chloro-substituted phenyl ring is known to influence lipophilicity and metabolic stability, which are critical factors in drug design. Preclinical studies have suggested that derivatives of this compound may exhibit properties relevant to treating neurological disorders, including modulation of neurotransmitter systems.

The synthesis of 2-(4-Chlorophenyl)Ethylamine Hydrochloride typically involves multi-step organic reactions, starting from readily available aromatic precursors. The chlorination step is crucial, often employing reagents such as phosphorus oxychloride or sulfuryl chloride to introduce the chloro group at the para position of the phenyl ring. Subsequent nucleophilic substitution reactions with ethylamine yield the desired amine derivative, which is then converted to the hydrochloride salt for improved stability and handling.

Recent advancements in medicinal chemistry have leveraged computational methods to predict the binding affinity and pharmacological activity of 2-(4-Chlorophenyl)Ethylamine Hydrochloride derivatives. Molecular docking studies have identified key interactions between this compound and target proteins, providing insights into potential mechanisms of action. These computational approaches have accelerated the drug discovery process, allowing researchers to prioritize promising candidates for further experimental validation.

The pharmacological profile of 2-(4-Chlorophenyl)Ethylamine Hydrochloride has been studied in various in vitro and in vivo models. Initial findings suggest that this compound may interact with monoamine transporters and receptors, making it a candidate for applications in mood regulation and neuroprotection. However, detailed toxicological assessments are essential to ensure safety before moving into clinical trials.

As part of broader efforts in neurological research, 2-(4-Chlorophenyl)Ethylamine Hydrochloride has been examined in contexts related to neurodegenerative diseases. Its structural features suggest potential interactions with pathways implicated in conditions such as Alzheimer's disease and Parkinson's disease. While these investigations are still in early stages, they highlight the compound's promise as a tool for understanding disease mechanisms and developing novel treatments.

The analytical characterization of 2-(4-Chlorophenyl)Ethylamine Hydrochloride relies on advanced spectroscopic techniques such as nuclear magnetic resonance (NMR), mass spectrometry (MS), and infrared (IR) spectroscopy. These methods confirm the molecular structure and purity of the compound, ensuring consistency for research applications. High-performance liquid chromatography (HPLC) is also commonly used for quantifying the compound in samples and formulations.

In conclusion, 2-(4-Chlorophenyl)Ethylamine Hydrochloride (CAS No. 2492-83-3) represents a compelling subject of study in pharmaceutical chemistry. Its unique structural features make it a valuable intermediate for drug development, particularly in areas related to central nervous system disorders. Ongoing research continues to uncover new possibilities for this compound, underscoring its importance in advancing therapeutic strategies.

• 38171-31-2(N-Methyl-4-chlorophenethylamine)
• 52516-20-8(2-(3-chlorophenyl)-N-methyl-ethanamine)
• 4806-79-5(2-(4-Chlorophenyl)propan-1-amine Hydrochloride)
• 16064-31-6(Benzeneethanamine,4-chloro-a-methyl-, hydrochloride, (R)-(9CI))
• 67851-51-8(2-(3,5-Dichlorophenyl)ethanamine)
• 13078-79-0(2-(3-Chlorophenyl)ethylamine)
• 13078-80-3(2-(2-Chlorophenyl)ethylamine)
• 156-41-2(2-(4-Chlorophenyl)ethylamine)
• 21581-45-3(3,4-Dichlorophenethylamine)
• 75425-55-7(2-(4-Chlorophenyl)propan-1-amine hydrochloride)